Graticule Asia Macro Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Graticule Asia Macro Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-85,500	Closed	-$9.64M	–	125
2015 Q4	$9.64M	Buy	+85,500	New	+$9.28M	1.57%	15
2015 Q3	–	Sell	-187,500	Closed	-$23.1M	–	111
2015 Q2	$23.1M	Buy	187,500 +72,000	+62%	+$8.62M	1.11%	13
2015 Q1	$13.2M	Buy	+115,500	New	+$12.7M	1.77%	14

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AWA

Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

CANY

Caxton Associates (New York) New York $3.18B AUM 54.49% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Graticule Asia Macro Advisors's IBB Position: Q4 2022 in Review

Graticule Asia Macro Advisors opened a new position in iShares Biotechnology ETF (IBB) in Q4 2022: 22,762 shares worth $2.99M. The stake represents 1.09% of the portfolio and ranks #18 among its holdings.

902 funds tracked by Wall St. Rank hold IBB as of Q4 2022.

Graticule Asia Macro Advisors held 22,762 shares of iShares Biotechnology ETF worth $2.99M as of Q4 2022.
iShares Biotechnology ETF was a new Graticule Asia Macro Advisors position in Q4 2022.
iShares Biotechnology ETF made up 1.09% of Graticule Asia Macro Advisors's portfolio in Q4 2022, its #18 holding.
902 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2022.

Based on Graticule Asia Macro Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.